NABTT 0502: a phase II and pharmacokinetic study of erlotinib and sorafenib for patients with progressive or recurrent glioblastoma multiforme.

BACKGROUND The signal transduction pathways of epidermal growth factor receptor and Ras are both important in the growth of glioblastoma multiforme (GBM). We hypothesized that inhibition of both pathways would improve the survival time of patients with recurrent GBM. METHODS Patients with recurrent/progressive GBM with 0-2 prior chemotherapy regimens received erlotinib 150 mg once daily and sorafenib 400 mg twice daily until progression. The primary endpoint was overall survival. Pharmacokinetic sampling was performed during cycle 1. RESULTS The median overall survival was 5.7 months. Progression-free survival at 6 months was 14%. Toxicity was manageable. Clearance of erlotinib was markedly enhanced by sorafenib. CONCLUSION The study did not meet its objective of a 30% increase in overall survival time compared with historical controls. Erlotinib and sorafenib have significant pharmacokinetic interactions that may negatively impact the efficacy of the combination regimen.

[1]  S. Phuphanich,et al.  Phase I trial of sorafenib in patients with recurrent or progressive malignant glioma. , 2011, Neuro-oncology.

[2]  Uwe Fuhr,et al.  Clinical Pharmacokinetics of Tyrosine Kinase Inhibitors , 2011, Clinical pharmacokinetics.

[3]  Sagar Agarwal,et al.  The Role of the Breast Cancer Resistance Protein (ABCG2) in the Distribution of Sorafenib to the Brain , 2011, Journal of Pharmacology and Experimental Therapeutics.

[4]  J. Beijnen,et al.  Erlotinib and pantoprazole: a relevant interaction or not? , 2010, British journal of clinical pharmacology.

[5]  R. McLendon,et al.  Phase II trial of bevacizumab and erlotinib in patients with recurrent malignant glioma. , 2010, Neuro-oncology.

[6]  E. Giovannetti,et al.  A Multicenter Phase II Study of Erlotinib and Sorafenib in Chemotherapy-Naïve Patients with Advanced Non–Small Cell Lung Cancer , 2010, Clinical Cancer Research.

[7]  L. Chin,et al.  Mutant EGFR is required for maintenance of glioma growth in vivo, and its ablation leads to escape from receptor dependence , 2010, Proceedings of the National Academy of Sciences.

[8]  J. Uhm.  Updated Response Assessment Criteria for High-Grade Gliomas: Response Assessment in Neuro-Oncology Working Group , 2010 .

[9]  W. Kaelin,et al.  Erlotinib therapy for central nervous system hemangioblastomatosis associated with von Hippel-Lindau disease: a case report , 2010, Journal of Neuro-Oncology.

[10]  Susan M. Chang,et al.  A phase II trial of erlotinib in patients with recurrent malignant gliomas and nonprogressive glioblastoma multiforme postradiation therapy. , 2010, Neuro-oncology.

[11]  Susan M. Chang,et al.  A phase I trial of erlotinib in patients with nonprogressive glioblastoma multiforme postradiation therapy, and recurrent malignant gliomas and meningiomas. , 2010, Neuro-oncology.

[12]  M. Prados,et al.  Phase I/II study of sorafenib and temsirolimus for patients with recurrent glioblastoma (GBM) (NABTC 05-02). , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  M. J. van den Bent,et al.  Randomized phase II trial of erlotinib versus temozolomide or carmustine in recurrent glioblastoma: EORTC brain tumor group study 26034. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  M. Prados,et al.  Phase I/II study of sorefenib and erlotinib for patients with recurrent glioblastoma (GBM) (NABTC 05-02). , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  C. Rudin,et al.  Pharmacogenomic and pharmacokinetic determinants of erlotinib toxicity. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  Keith L. Ligon,et al.  Coactivation of Receptor Tyrosine Kinases Affects the Response of Tumor Cells to Targeted Therapies , 2007, Science.

[17]  G. Pond,et al.  Phase I Targeted Combination Trial of Sorafenib and Erlotinib in Patients with Advanced Solid Tumors , 2007, Clinical Cancer Research.

[18]  Forest M White,et al.  Quantitative analysis of EGFRvIII cellular signaling networks reveals a combinatorial therapeutic strategy for glioblastoma , 2007, Proceedings of the National Academy of Sciences.

[19]  Sumithra J. Mandrekar,et al.  Phase I Trial of Sorafenib in Combination with Gefitinib in Patients with Refractory or Recurrent Non–Small Cell Lung Cancer , 2007, Clinical Cancer Research.

[20]  M. Hidalgo,et al.  Assessment of erlotinib pharmacodynamics in tumors and skin of patients with head and neck cancer. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

[21]  B. Lum,et al.  The effects of CYP3A4 inhibition on erlotinib pharmacokinetics: computer-based simulation (SimCYP™) predicts in vivo metabolic inhibition , 2007, European Journal of Clinical Pharmacology.

[22]  R. Pazdur,et al.  Sorafenib for the Treatment of Advanced Renal Cell Carcinoma , 2006, Clinical Cancer Research.

[23]  R. Bruno,et al.  Clinical pharmacokinetics of erlotinib in patients with solid tumors and exposure‐safety relationship in patients with non–small cell lung cancer , 2006, Clinical pharmacology and therapeutics.

[24]  J. Raizer,et al.  Erratum: Molecular study of malignant gliomas treated with epidermal growth factor receptor inhibitors: Tissue analysis from North American Brain Tumor Consortium Trials 01-03 and 00-01 (Clinical Cancer Research (November 1, 2005) 11 (7841-7850)) , 2006 .

[25]  Susan Chang,et al.  Phase 1 study of erlotinib HCl alone and combined with temozolomide in patients with stable or recurrent malignant glioma. , 2006, Neuro-oncology.

[26]  Koji Yoshimoto,et al.  Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. , 2005, The New England journal of medicine.

[27]  Susan M. Chang,et al.  Molecular Study of Malignant Gliomas Treated with Epidermal Growth Factor Receptor Inhibitors: Tissue Analysis from North American Brain Tumor Consortium Trials 01-03 and 00-01 , 2005, Clinical Cancer Research.

[28]  A. Oza,et al.  Phase I study to determine the safety and pharmacokinetics of the novel Raf kinase and VEGFR inhibitor BAY 43-9006, administered for 28 days on/7 days off in patients with advanced, refractory solid tumors. , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

[29]  Jeffrey W. Clark,et al.  Safety and Pharmacokinetics of the Dual Action Raf Kinase and Vascular Endothelial Growth Factor Receptor Inhibitor, BAY 43-9006, in Patients with Advanced, Refractory Solid Tumors , 2005, Clinical Cancer Research.

[30]  M. Piccart,et al.  Phase I safety and pharmacokinetics of BAY 43-9006 administered for 21 days on/7 days off in patients with advanced, refractory solid tumours , 2005, British Journal of Cancer.

[31]  Martin J. van den Bent,et al.  Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. , 2005, The New England journal of medicine.

[32]  Dirk Strumberg,et al.  Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  J. Holmlund,et al.  Efficacy and toxicity of the antisense oligonucleotide aprinocarsen directed against protein kinase C-alpha delivered as a 21-day continuous intravenous infusion in patients with recurrent high-grade astrocytomas. , 2005, Neuro-oncology.

[34]  L. Ellis,et al.  Molecular mechanisms of resistance to therapies targeting the epidermal growth factor receptor. , 2005, Clinical cancer research : an official journal of the American Association for Cancer Research.

[35]  S. Steinberg,et al.  Evaluation of biologic end points and pharmacokinetics in patients with metastatic breast cancer after treatment with erlotinib, an epidermal growth factor receptor tyrosine kinase inhibitor. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[36]  G. Barnett,et al.  Phase II trial of the EGFR tyrosine kinase inhibitor erlotinib for single agent therapy of recurrent Glioblastoma Multiforme: Interim results. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[37]  W. Yung,et al.  The autocrine loop of TGF-α/EGFR and brain tumors , 1997, Journal of Neuro-Oncology.

[38]  X Yu,et al.  J.Chromatogr., B: Anal. Technol. Biomed. Life Sci. , 2004 .

[39]  T. Mikkelsen,et al.  Phase 2 study of weekly irinotecan in adults with recurrent malignant glioma: final report of NABTT 97-11. , 2004, Neuro-oncology.

[40]  M. Hidalgo,et al.  Specific method for determination of OSI-774 and its metabolite OSI-420 in human plasma by using liquid chromatography-tandem mass spectrometry. , 2003, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[41]  T. Efferth,et al.  EGFR but not PDGFR-beta expression correlates to the antiproliferative effect of growth factor withdrawal in glioblastoma multiforme cell lines. , 2003, Anticancer research.

[42]  M. Hidalgo,et al.  Development of the epidermal growth factor receptor inhibitor Tarceva (OSI-774). , 2003, Advances in experimental medicine and biology.

[43]  Arnab Chakravarti,et al.  Insulin-like growth factor receptor I mediates resistance to anti-epidermal growth factor receptor therapy in primary human glioblastoma cells through continued activation of phosphoinositide 3-kinase signaling. , 2002, Cancer research.

[44]  L. Grochow,et al.  Toxicity, efficacy, and pharmacology of suramin in adults with recurrent high-grade gliomas. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[45]  E K Rowinsky,et al.  Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[46]  D. Gutmann,et al.  Astrocyte-specific expression of activated p21-ras results in malignant astrocytoma formation in a transgenic mouse model of human gliomas. , 2001, Cancer research.

[47]  A. Pawson,et al.  Proliferation of human malignant astrocytomas is dependent on Ras activation , 1997, Oncogene.

[48]  A Bye,et al.  Common noncompartmental pharmacokinetic variables: are they normally or log-normally distributed? , 1997, Journal of biopharmaceutical statistics.

[49]  W. Yung,et al.  The autocrine loop of TGF-alpha/EGFR and brain tumors. , 1997, Journal of neuro-oncology.

[50]  M Kiessling,et al.  Amplification of the epidermal‐growth‐factor‐receptor gene correlates with different growth behaviour in human glioblastoma , 2007, International journal of cancer.

[51]  O D Laerum,et al.  Effect of epidermal growth factor on glioma cell growth, migration, and invasion in vitro. , 1990, Cancer research.

[52]  T. Cascino,et al.  Response criteria for phase II studies of supratentorial malignant glioma. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[53]  E. Mizuta,et al.  Preparation of mean drug concentration--time curves in plasma. A study on the frequency distribution of pharmacokinetic parameters. , 1985, Chemical & pharmaceutical bulletin.

[54]  P. Echlin,et al.  Amplification and overexpression of the EGF receptor gene in primary human glioblastomas , 1985 .

[55]  P. Echlin,et al.  Amplification and Overexpression of the EGF Receptor Gene in Primary Human Glioblastomas , 1985, Journal of Cell Science.

[56]  Hermona Soreq,et al.  Amplification, enhanced expression and possible rearrangement of EGF receptor gene in primary human brain tumours of glial origin , 1985, Nature.

[57]  Rupert G. Miller.  The jackknife-a review , 1974 .